MCID: MTR014
MIFTS: 58

Motor Neuron Disease malady

Category: Neuronal diseases

Aliases & Classifications for Motor Neuron Disease

About this section

Aliases & Descriptions for Motor Neuron Disease:

Name: Motor Neuron Disease 35 11 50 13 68
 
Motor Neuron Diseases 49

Classifications:



External Ids:

Disease Ontology11 DOID:231
ICD1030 G12.2, G12.20
ICD9CM32 335.2
MeSH39 D016472

Summaries for Motor Neuron Disease

About this section
NINDS:49 The motor neuron diseases (MNDs) are a group of progressive neurological disorders that destroy cells that control essential muscle activity such as speaking, walking, breathing, and swallowing.  Normally, messages from nerve cells in the brain (called upper motor neurons) are transmitted to nerve cells in the brain stem and spinal cord (called lower motor neurons) and from them to particular muscles.  When there are disruptions in these signals, the result can be gradual muscle weakening, wasting away, and uncontrollable twitching (called fasciculations).  Eventually, the ability to control voluntary movement can be lost.  MNDs may be inherited or acquired, and they occur in all age groups.  MNDs occur more commonly in men than in women, and symptoms may appear after age 40.  In children, particularly in inherited or familial forms of the disease, symptoms can be present at birth or appear before the child learns to walk.

MalaCards based summary: Motor Neuron Disease, also known as motor neuron diseases, is related to madras motor neuron disease and amyotrophic lateral sclerosis 1, and has symptoms including ataxia, muscular fasciculation and hemiplegia. An important gene associated with Motor Neuron Disease is TARDBP (TAR DNA Binding Protein), and among its related pathways are Cytoskeleton remodeling Neurofilaments and Cytoskeletal Signaling. Affiliated tissues include the motor neurones, spinal cord and brain, and related mouse phenotypes are liver/biliary system and integument.

Disease Ontology:11 A neurodegenerative disease that is located in the motor neurones.

Wikipedia:71 A motor neuron disease (MND) is any of several neurological disorders that selectively affect motor... more...

Related Diseases for Motor Neuron Disease

About this section

Diseases related to Motor Neuron Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 176)
idRelated DiseaseScoreTop Affiliating Genes
1madras motor neuron disease12.4
2amyotrophic lateral sclerosis 111.9
3lateral sclerosis11.8
4frontotemporal dementia and/or amyotrophic lateral sclerosis 111.6
5dementia, frontotemporal11.6
6progressive muscular atrophy11.3
7juvenile amyotrophic lateral sclerosis11.3
8spinal muscular atrophy, distal, autosomal recessive, 411.2
9spinal muscular atrophy11.1
10spinal and bulbar muscular atrophy of kennedy11.1
11hereditary spastic paraplegia11.1
12neuropathy, distal hereditary motor, type viib11.1
13progressive bulbar palsy11.0
14neuronitis11.0
15amyotrophy, monomelic10.9
16pontocerebellar hypoplasia, type 1c10.7
17pick disease10.7
18supranuclear palsy, progressive10.7
19spastic paraplegia 39, autosomal recessive10.7
20spinal muscular atrophy, jokela type10.7
21silver spastic paraplegia syndrome10.7
22patulous eustachian tube10.7
23benign focal amyotrophy10.7
24o'sullivan-mcleod syndrome10.7
25dementia10.5
26posterior polar cataract10.3SMN1, SMN2
27spinal cord glioma10.3SMN1, SMN2, TARDBP
28fanconi anemia, complementation group g10.3ALS2, SOD1
29colorado tick fever10.3SMN1, SMN2, TARDBP
30protein r deficiency10.3GRN, MAPT
31gata1-related thrombocytopenia10.3GRN, MAPT
32social emotional agnosia10.3GRN, TARDBP
33spinal muscular atrophy-410.3NAIP, SMN1, SMN2
34hereditary paraganglioma-pheochromocytoma syndromes10.3GRN, MAPT
35glomerulopathy with fibronectin deposits 210.3ALS2, CNTF
36pigmented nodular adrenocortical disease, primary, 310.3SMN1, SMN2
37color agnosia10.3GRN, TARDBP
38pseudohermaphrodism anorectal anomalies10.3NAIP, SMN1, SMN2
39sting-associated vasculopathy, infantile-onset10.3SOD1, TARDBP, VCP
40fanconi renotubular syndrome 110.3MAPT, RAB5A, TARDBP
41neurosarcoidosis10.3MAPT, SLC1A2, SOD1
42spinal muscular atrophy-310.3NAIP, SMN1, SMN2
43osteogenesis imperfecta, type vi10.3SOD1, TARDBP
44epithelioid type angiomyolipoma10.2CNTF, MAPT, SOD1, TARDBP
45neuropathy10.2
46acrofrontofacionasal dysostosis10.2GRN, MAPT, TARDBP
47adrenal cortical adenoma10.2SQSTM1, TARDBP, VCP
48postauricular lymphadenitis10.2GRN, MAPT, TARDBP
49acne inversa, familial, 310.2MAPT, SQSTM1, TARDBP
50autoimmune disease of urogenital tract10.2GRN, MAPT, TARDBP

Comorbidity relations with Motor Neuron Disease via Phenotypic Disease Network (PDN):


Amyotrophic Lateral Sclerosis 1

Graphical network of the top 20 diseases related to Motor Neuron Disease:



Diseases related to motor neuron disease

Symptoms & Phenotypes for Motor Neuron Disease

About this section

UMLS symptoms related to Motor Neuron Disease:


ataxia, muscular fasciculation, hemiplegia, myoclonus

MGI Mouse Phenotypes related to Motor Neuron Disease according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.9AR, BSCL2, GRN, HEXA, SOD1, SOD2
2MP:00107719.8AR, BSCL2, MAPT, SMN2, SOD1, SOD2
3MP:00053699.7ALS2, AR, CNTF, MAPT, SMN2, SOD1
4MP:00053879.3ALS2, AR, BSCL2, CNTF, GRN, MAPT
5MP:00053979.2AR, BSCL2, CNTF, GRN, MAPT, RAB5A
6MP:00053789.0ALS2, AR, BSCL2, HEXA, MAPT, SLC1A2
7MP:00053848.8AR, BSCL2, CNTF, DCTN1, GRN, MAPT
8MP:00107688.7ALS2, AR, BSCL2, DCTN1, GRN, HEXA
9MP:00053768.5ALS2, AR, BSCL2, CNTF, DCTN1, GRN
10MP:00053868.4ALS2, AR, BSCL2, CNTF, DCTN1, GRN
11MP:00036317.5ALS2, AR, CNTF, DCTN1, GRN, HEXA

Drugs & Therapeutics for Motor Neuron Disease

About this section

Drugs for Motor Neuron Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 372)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
Riluzoleapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1651744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
3
MentholapprovedPhase 426062216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
4
MexiletineapprovedPhase 4, Phase 22031828-71-44178
Synonyms:
(+-)-1-(2,6-Dimethylphenoxy)propan-2-amine
(+-)-1-(2,6-dimethylphenoxy)propan-2-amine
(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane
1-(2',6'-Dimethylphenoxy)-2-aminopropane
1-(2,6-Dimethylphenoxy)-2-propanamine
1-(2,6-dimethylphenoxy)propan-2-amine
1-Methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethylamine
1-methyl-2-(2,6-xylyloxy)ethanamine
2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride
2-(2-aminopropoxy)-1,3-dimethylbenzene
31828-71-4
5370-01-4 (hydrochloride)
AB00053683
AC1L1HL7
AC1Q2BC5
AC1Q2BC6
BPBio1_000026
BRD-A64092382-003-04-3
BRN 2092205
BSPBio_000022
BSPBio_002254
C07220
CHEBI:115958
CHEBI:6916
CHEMBL558
CID4178
D08215
DB00379
DivK1c_000834
EINECS 250-825-7
I01-6374
IDI1_000834
KBio1_000834
KBio2_002082
KBio2_004650
 
KBio2_007218
KBio3_001474
KBioGR_001270
KBioSS_002082
KO-1173
KO1173
KOE-1173
LS-68257
Lopac0_000784
Mexiletene
Mexiletina
Mexiletina [INN-Spanish]
Mexiletine
Mexiletine (INN)
Mexiletine HCL
Mexiletine [INN:BAN]
Mexiletinum
Mexiletinum [INN-Latin]
Mexilitine
Mexilétine
Mexitil
Mexityl
MolPort-001-790-944
NCGC00015659-04
NCGC00162253-01
NCGC00162253-02
NINDS_000834
Prestwick0_000241
Prestwick1_000241
Prestwick2_000241
Prestwick3_000241
SBB070242
SPBio_002241
Spectrum3_000727
Spectrum4_000795
Spectrum5_001279
Spectrum_001602
UNII-1U511HHV4Z
5
DextromethorphanapprovedPhase 4, Phase 3, Phase 2133125-71-35360696, 5362449
Synonyms:
( )-3-Methoxy-N-methylmorphinon
( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren
(+)-3-Methoxy-17-methylmorphinan
(+)-dextromethorphan
(-)-3-Methoxy-N-methylmorphinan
(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan
125-69-9 (hydrobromide)
125-70-2
125-71-3
18046-32-7
18609-21-7 (hydrochloride)
3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan
3-Methoxy-17-methylmorphinan
32062-10-5
4-21-00-01367 (Beilstein Handbook Reference)
6700-34-1 (hydrobromide, mono-hydrate)
9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI)
AC-13098
AC1L1EYT
Albutussin
Antussan
BA 2666
BPBio1_000503
BRD-K33211335-337-03-7
BRN 0088549
BSPBio_000457
Balminil DM
Balminil DM Children
Bayer Select Flu Relief
Bayer Select Head & Chest Cold
Bayer Select Night Time Cold
Benylin Adult Formula Cough Suppressant
Benylin DM
Benylin DM (TN)
Benylin DM 12 Hour
Benylin DM for Children
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
C06947
CHEBI:128891
CHEBI:4470
CHEBI:580686
CHEMBL22207
CHEMBL52440
CID3008
CID5360696
CID5362449
Calmylin #1
Canfodion
Cerose-DM
Chloraseptic DM
Contac Day & Night Cold/Flu Day Caplets
Contac Jr. Non-drowsy Formula
Contac Nighttime Cold Medicine
Contac Severe Cold Formula Maximum Strength
Contac Severe Cold Formula Non-Drowsy
Coricidin Syrup
Cosylan
Cough-X
Creo-Terpin
D-Methorphan
D-Methorphan Hydrobromide
D-methorphan
D03742
DB00514
DEA No. 9210
DM
DXM
Delsym
Delsym Cough Formula
Delta-Methorphan
Demorphan
Demorphan Hydrobromide
Demorphan hydrobromide
Demorphine
Destrometerfano
Destrometerfano [DCIT]
Destrometerfano [Dcit]
Dex
Dextromethorfan
Dextromethorfan [Czech]
Dextromethorphan
Dextromethorphan (USP)
Dextromethorphan Bromhydrate
Dextromethorphan Bromide
Dextromethorphan [USP:INN:BAN]
Dextromethorphan hydrobromide OROS Tablets
Dextromethorphan hydrobromide [BAN:JAN]
Dextromethorphan hydrobromide monohydrate
Dextromethorphane
Dextromethorphane [INN-French]
Dextromethorphanum
Dextromethorphanum [INN-Latin]
Dextrometorfano
Dextrometorfano [INN-Spanish]
Dextrometorphan
Dextromorphan
Dextrométhorphane
Dexyromethorphan
Diabe-Tuss DM Syrup
 
Dimacol
Dimetapp DM
Dormetan
Dormethan
Drixoral Cough
Drixoral Cough & Congestion
Drixoral Cough & Sore Throat
EINECS 204-751-7
EINECS 204-752-2
Endotussin-NN
Endotussin-NN Pediatric
HMS2090C08
HSDB 3056
Hihustan M.
Hold
Hold DM
Koffex DM
L-Methorphan
LS-91837
LS-91838
Levomethorphan
Levomethorphan [BAN:DCF:INN]
Levomethorphan [Ban:Dcf:Inn]
Levomethorphan [INN:BAN:DCF]
Levomethorphane
Levomethorphane [INN-French]
Levomethorphanum
Levomethorphanum [INN-Latin]
Levometorfano
Levometorfano [INN-Spanish]
Lopac-D-2531
Lopac0_000337
MLS000758303
Medicon
Methorate
Methorate Hydrobromide
Methorphan
Metrorat
MolPort-003-940-943
MolPort-004-285-957
Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI)
NCGC00015333-01
NCGC00015333-02
NCGC00015333-04
NCGC00162126-01
Naldecon-DX
Novahistex DM
Novahistine DM
Ornex Severe Cold Formula
Orthoxicol
PediaCare 1
PediaCare Cough-Cold Formula
Pertussin CS Children's Strength
Pertussin DM Extra Strength
Prestwick0_000359
Prestwick1_000359
Prestwick2_000359
Prestwick3_000359
Prestwick_686
RACEMETHORPHAN
Robitussin CF
Robitussin Cold & Cough
Robitussin Cough Calmers
Robitussin DM
Robitussin Maximum Strength Cough
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Robitussin Pediatric Cough
Robitussin Pediatric Cough & Cold
Robitussin Pediatric Cough Suppressant
Robitussin Pediatric Night Relief
Romilar
Rondec dm
Ru-Tuss Expectorant
SPBio_002378
St. Joseph Cough Syrup
Sucrets 4 Hour Cough Suppressant
Sudafed Cough Syrup
Triaminic
Triaminic DM Long Lasting for Children
Trind-DM
Trocal
Tusilan
Tussade
Tussar DM
Tussi-Organidin
Tussi-Organidin DM NR
Tussi-Organidin DM-S NR
Tylenol Cold No Drowsiness
Tylenol Cold and Flu Multi-Symptom
Tylenol Cold and Flu No Drowsiness
Tylenol Cough + Decongestant Liquid
Tylenol Cough Liquid
Tylenol Flu No Drowsiness Gelcaps
UNII-7355X3ROTS
Vicks 44 Cough Relief
Viro-Med
d-Methorphan
delta-Methorphan
dextromethorphan
l-Methorphan
6
Pramipexoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1139104632-26-059868, 119570
Synonyms:
(-)-Pramipexole
(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole
(S)-N  6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine
104632-26-0
111GE001
2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole
2-amino-6-propylaminotetrahydrobenzothiazole
AC1L3P1T
BIDD:GT0250
C10H17N3S
CHEBI:8356
CHEMBL301265
CID119570
CPD000449298
D05575
DivK1c_006916
Furfuryl Acetate
HMS2051A21
HMS2090C15
KBio1_001860
KBio2_002340
KBio2_004908
 
KBio2_007476
KBioSS_002343
LS-40722
MLS000758250
MLS001423952
Mirapex
MolPort-003-849-957
NCGC00167441-01
Pramipexol
Pramipexol [Spanish]
Pramipexole
Pramipexole (USAN/INN)
Pramipexole 2HCl Monohydrate
Pramipexole [USAN:INN]
Pramipexole hydrochloride
Pramipexolum
Pramipexolum [Latin]
SAM001247006
SBB070477
SMR000449298
SND-919
SUD919CL2Y
SpecPlus_000820
Spectrum5_001453
Spectrum_001838
U-98528E
pramipexole
7
Guaifenesinapproved, vet_approvedPhase 4, Phase 3, Phase 264193-14-13516
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
Amonidren
Amonidrin
Aresol
Benylin-E
Bronchol
Glycerin ether
Glycerin guaiacolate
Glycero-guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
Glyceryl guiacolate
 
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesin
Guaifenesine
Guaiphenesin
Guaiphenesine
Guaiphesin
Hustosil
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
Pneumomist
Propanosedyl
Reduton
Robitussin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
guaiphenesin
p-Cresyl acetate
8
GoserelinapprovedPhase 423365807-02-547725, 5311128
Synonyms:
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
AC1NSK1T
CID5311128
Goserelin
Goserelin acetate
 
HMS2089D16
HS-2015
ICI-118630
MolPort-006-823-831
ZD-9393
Zoladex
goserelin
9
CycloserineapprovedPhase 410868-41-7401, 6234
Synonyms:
(+)-4-Amino-3-isoxazolidinone
(+)-Cycloserine
(4R)-4-Amino-3-isoxazolidinone
(4R)-4-amino-1,2-oxazolidin-3-one
(4R)-4-aminoisoxazolidin-3-one
(R)-(+)-4-Amino-3-isoxazolidinone
(R)-(+)-Cycloserine
(R)-4-AMINO-ISOXAZOLIDIN-3-ONE
(R)-4-AMINO-isoxazolidin-3-one
(R)-4-Amino-3-isoxazolidinone
(R)-4-Amino-3-isoxazolidone
(R)-Cycloserine
1pb9
3-Isoxazolidinone, 4-amino-, (+)- (8CI)
3-Isoxazolidinone, 4-amino-, (4R)- (9CI)
3-Isoxazolidinone, 4-amino-, (R)
3-Isoxazolidinone, 4-amino-, D
30020_FLUKA
30020_SIGMA
4-27-00-05549 (Beilstein Handbook Reference)
4AX
68-41-7
AB00443920
AC-4721
AC1L1M33
AC1Q4UA7
AI3-50153
BB_NC-1631
BIDD:GT0707
BPBio1_001252
BRN 0080798
BSPBio_001138
BSPBio_002121
C 3909
C-9390
C-9400
C08057
C3909_SIGMA
C3H6N2O2
C6880_SIGMA
C7670_SIGMA
CAS-339-72-0
CAS-68-41-7
CHEBI:40009
CHEMBL771
CID6234
CPD-2482
CPD000058313
Cicloserina
Cicloserina [INN-Spanish]
Cicloserina [Italian]
Closerin
Closina
Cyclo-D-serine
Cyclorin
Cycloserine
Cycloserine (JP15/USP/INN)
Cycloserine [INN:BAN:JAN]
Cycloserinum
Cycloserinum [INN-Latin]
D-(+)-Cycloserine
D-4-Amino-3-isossazolidone
D-4-Amino-3-isossazolidone [Italian]
D-4-amino-3-Isoxazolidinone
D-4-amino-3-Isoxazolidone
D-4-amino-3-isoxazolidinone
D-4-amino-3-isoxazolidone
D-CS
D-Cycloserine
D-Cycloserine synth. BP 88
D-Cycloserine, synthetic
D-Oxamicina
D-Oxamycin
D-amino-3-isoxazolidinone
D-cycloserine
D00877
DB03123
DCS
DL-Cycloserine
DRG-0195
DivK1c_000098
E-733-A
EINECS 200-688-4
 
EU-0100252
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09
Farmiserina
HMS1571I20
HMS1920C06
HMS2051C15
HMS2091I14
HMS500E20
HSDB 3218
I-1431
IDI1_000098
K-300
KBio1_000098
KBio2_001340
KBio2_003908
KBio2_006476
KBio3_001341
KBioGR_000890
KBioSS_001340
L-Cycloserine
LMPK14000007
LS-86757
Lopac-C-1159
Lopac-C-3909
Lopac-C-7005
Lopac0_000252
MLS000758215
MLS001423962
Micoserina
Miroserina
Miroseryn
MolPort-000-858-643
NCGC00015213-01
NCGC00015213-02
NCGC00015213-03
NCGC00016306-01
NCGC00016306-02
NCGC00016306-03
NCGC00016306-05
NCGC00093713-01
NCGC00093713-02
NINDS_000098
NSC 154851
Novoserin
Orientomycin
Oxamicina
Oxamicina [Italian]
Oxamycin
PA 94
PA-94
Prestwick0_001089
Prestwick1_001089
Prestwick2_001089
Prestwick3_001089
R(+)-4-Amino-3-isoxazolidinone
R-(+)-Cycloserine
R-4-Amino-3-isoxazolidinone
RO-1-9213
Ro-1-9213
S1998_Selleck
SAM001247014
SAM002264599
SC-49088
SMP1_000167
SMR000058313
SPBio_000008
SPBio_003029
SPECTRUM1500215
Seromycin
Seromycin (TN)
Spectrum2_000084
Spectrum3_000371
Spectrum4_000305
Spectrum5_000797
Spectrum_000860
Tebemicina
Tisomycin
UNII-95IK5KI84Z
Wasserina
alpha-Cycloserine
cyclo-D-Serine
cycloserine
orientomycin
α-Cycloserine
10Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 213180
11HormonesPhase 4, Phase 3, Phase 1, Phase 214415
12Neuroprotective AgentsPhase 4, Phase 2, Phase 3, Phase 11716
13Excitatory Amino AcidsPhase 4, Phase 2, Phase 31362
14AnticonvulsantsPhase 4, Phase 2, Phase 3, Phase 12695
15Excitatory Amino Acid AntagonistsPhase 4, Phase 2, Phase 31347
16Anti-Arrhythmia AgentsPhase 4, Phase 3, Phase 23093
17Dopamine AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13836
18Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 118340
19Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 1, Phase 213168
20Protective AgentsPhase 4, Phase 2, Phase 3, Phase 17443
21AntioxidantsPhase 4, Phase 3, Phase 2, Phase 13050
22Antiparkinson AgentsPhase 4, Phase 3, Phase 2, Phase 11574
23Antineoplastic Agents, HormonalPhase 4, Phase 1, Phase 25592
24Adrenocorticotropic HormonePhase 4, Phase 2164
25beta-endorphinPhase 4, Phase 2140
26Respiratory System AgentsPhase 4, Phase 3, Phase 2, Phase 14997
27Melanocyte-Stimulating HormonesPhase 4, Phase 2139
28Dopamine agonistsPhase 4, Phase 3, Phase 2, Phase 1632
29Sodium Channel BlockersPhase 4, Phase 3, Phase 21593
30Diuretics, Potassium SparingPhase 4, Phase 3, Phase 21917
31Chlorpheniramine, phenylpropanolamine drug combinationPhase 4, Phase 3, Phase 2641
32Antibiotics, AntitubercularPhase 4, Phase 3, Phase 27180
33Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
34AntimetabolitesPhase 4, Phase 2, Phase 112054
35Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 122062
36Antitussive AgentsPhase 4, Phase 3, Phase 2542
37Antitubercular AgentsPhase 41343
38Renal AgentsPhase 4754
39
Olanzapineapproved, investigationalPhase 2, Phase 3399132539-06-14585
Synonyms:
132539-06-1
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10 H -thieno[2,3- b ] [1,5]benzodiazepine
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine
AC-665
AC1L1IHS
AKOS000282888
ALKS-7921
BIDD:GT0332
BIDD:PXR0138
Bio-0169
C07322
C076029
C17H20N4S
CHEBI:7735
CHEMBL715
CID4585
CPD000466345
D00454
DB00334
Eli Lilly brand of olanzapine
HMS2051H05
HMS2089M04
HMS2093I04
I06-0784
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H
InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
Jsp001969
KS-1090
L000455
L005958
LS-152313
LY 170053
LY-170052
 
LY-170053
Lanzac
Lilly brand of olanzapine
MLS000759457
MLS001165781
MLS001195646
MLS001424057
Midax
MolPort-002-885-845
MolPort-003-666-569
MolPort-005-977-341
NCGC00096077-01
NCGC00096077-03
NCGC00096077-04
Olansek
Olanzapin
Olanzapina
Olanzapine
Olanzapine (JAN/USAN/INN)
Olanzapine (OLA)
Olanzapine [USAN:INN]
Olanzapinum
S2493_Selleck
SAM001246652
SMR000466345
SPECTRUM1505024
STK634338
Symbyax
TL8000772
UNII-N7U69T4SZR
Zalasta
Zydis
Zyprexa
Zyprexa (TN)
Zyprexa Intramuscular
Zyprexa Velotab
Zyprexa Zydis
olanzapina
olanzapine
olanzapinum
40
AcetylcholineapprovedPhase 3, Phase 2, Phase 180551-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
O-Acetylcholine
acetylcholine chloride
41
LevodopaapprovedPhase 3, Phase 240259-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
42
LenograstimapprovedPhase 2, Phase 31220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
43
Memantineapproved, investigationalPhase 2, Phase 318119982-08-24054
Synonyms:
1,3-Dimethyl-5-adamantanamine
1-Amino-3,5-dimethyladamantane
19982-08-2
3,5-Dimethyl-1-adamantanamine
3,5-Dimethyl-1-adamantylamine
3,5-Dimethyl-1-aminoadamantane
3,5-Dimethyladamantan-1-ylamine
3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine
3,5-dimethyladamantan-1-amine
3,5-dimethyltricyclo[3.3.1.1~3,7~]decan-1-amine
41100-52-1 (Hydrochloride)
51052-62-1
AB00053600
AC1L1HB7
AKOS000113995
BBL000737
BPBio1_001117
BPBio1_001270
BSPBio_001015
Biomol-NT_000209
C13736
CBMicro_020348
CHEBI:152523
CHEMBL807
CID4054
D08174
DB01043
DMAA
DivK1c_000068
EU-0053634
Ebixa
Exiba
Exiba (TN)
HMS500D10
HSDB 7327
IDI1_000068
KBio1_000068
KBio2_001087
KBio2_003655
 
KBio2_006223
KBio3_001926
KBioGR_001543
KBioSS_001087
LS-157051
Lopac0_000861
Memantin
Memantina
Memantina [INN-Spanish]
Memantine
Memantine (INN)
Memantine HCL
Memantine Hydrochloride
Memantine [INN:BAN]
Memantine [INN]
Memantinum
Memantinum [INN-Latin]
MolPort-002-041-858
NCGC00015705-05
NCGC00024782-02
NCGC00024782-03
NINDS_000068
Namenda
Oprea1_480562
Prestwick0_000978
Prestwick1_000978
Prestwick2_000978
Prestwick3_000978
SPBio_001456
SPBio_002926
ST057652
STK520682
Spectrum2_001408
Spectrum3_000923
Spectrum4_001022
Spectrum5_001355
Spectrum_000607
UNII-W8O17SJF3T
ZERO/006024
memantine
44
HydroxyureaapprovedPhase 2, Phase 3, Phase 1223127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
45
CitalopramapprovedPhase 3, Phase 151259729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
46
AmantadineapprovedPhase 367768-94-52130
Synonyms:
1-Adamantamine
1-Adamantanamine
1-Adamantanamine (8CI)
1-Adamantylamine
1-Aminoadamantane
1-Aminotricyclo(3.3.1.1(sup 3,7))decane
1-adamantanamine
1-adamantylamine
1-aminoadamantane
138576_ALDRICH
665-66-7 (hydrochloride)
768-94-5
AB00514655
AC-11992
AC1L1CZI
AC1Q4UAF
AC1Q5396
ADAMANTANE,1-AMINO
AKOS000113994
AKOS000119324
Adamantamine
Adamantanamine
Adamantylamine
Amant
Amantadina
Amantadina [INN-Spanish]
Amantadine
Amantadine (INN)
Amantadine Base
Amantadine HCL
Amantadine Hydrochloride
Amantadine [INN:BAN]
Amantadinum
Amantadinum [INN-Latin]
Amantidine
Ambap768-94-5
Aminoadamantane
BIA4304
BIDD:GT0757
BPBio1_000368
BRN 2204333
BSPBio_000334
BSPBio_001570
BSPBio_001822
Bio-0821
C06818
C10H17N
CHEBI:2618
CHEMBL660
CID2130
D07441
DB00915
DivK1c_000815
EINECS 212-201-2
Endantadine
Gen-Amantadine
HMS1791O12
HMS1989O12
HSDB 3202
I14-1101
IDI1_000815
InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H
KBio1_000815
KBio2_000390
 
KBio2_002958
KBio2_005526
KBio3_001322
KBioGR_000548
KBioSS_000390
L000868
LS-157049
Lopac-A-1260
Lopac0_000004
Mantadine
MolPort-001-661-700
MolPort-001-760-587
MolPort-001-791-102
NCGC00015036-01
NCGC00015036-07
NCGC00162039-01
NCGC00162039-02
NCGC00162039-03
NCGC00162039-04
NCGC00179597-01
NCIOpen2_001059
NINDS_000815
NSC 341865
NSC341865
NSC83653
OR14310
Oprea1_248648
Pk-Merz
Pk-merz
Prestwick0_000407
Prestwick1_000407
Prestwick2_000407
Prestwick3_000407
SPBio_000002
SPBio_002273
STK298781
Spectrum2_000081
Spectrum3_000291
Spectrum4_000134
Spectrum5_000772
Spectrum_000030
Symadine
Symmetrel
TCMDC-125869
TL8005280
Tricyclo(3.3.1.1(3,7))-decan-1-amine
Tricyclo(3.3.1.1(sup 3,7))decan-1-amine
Tricyclo(3.3.1.1(sup 3.7))decan-1-amine
Tricyclo(3.3.1.13,7)decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-amine
Tricyclo[3.3.1.1(3,7)]decan-1-ylamine
Tricyclo[3.3.1.1(3,7)]decane-1-amine
Tricyclo[3.3.1.1(sup3,7)]decan-1-amine
Tricyclo[3.3.1.1^3,7]decan-1-amine
UNII-BF4C9Z1J53
Viregyt
Virosol
WLN: L66 B6 A B- C 1B ITJ BZ
Wiregyt
adamantan-1-amine
adamantan-1-ylamine
amantadine
amantadine hydrochloride
tricyclo[3.3.1.1(3,7)]decan-1-ylamine
tricyclo[3.3.1.1(3,7)]decane-1-amine
tricyclo[3.3.1.1~3,7~]decan-1-amine
47
Ropiniroleapproved, investigationalPhase 37491374-20-8, 91374-21-95095, 497540
Synonyms:
1,3-Dihydro-4-(2-(dipropylamino)ethyl)-2H-indol-2-one monohydrochloride
2(H)-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-, monohydrochloride
2H-Indol-2-one, 1,3-dihydro-4-(2-(dipropylamino)ethyl)-, monohydrochloride
2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, hydrochloride (1:1)
4-(2-(Dipropylamino)ethyl)-2-indolinone monohydrochloride
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(Dipropylamino)ethyl]indoline-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one hydrochloride
91374-20-8
91374-20-8 (hydrochloride)
91374-21-9
91374-21-9 (Parent)
AB1004799
AC-735
AC1L1JLL
AC1L2ABS
AC1Q3EQJ
AR-1L3132
Adartrel
BIDD:GT0826
BRD-K15933101-003-01-2
C07564
CHEBI:8888
CHEMBL1200411
CHEMBL589
CID5095
CID68727
D00784
D08489
DB00268
EU-0101101
HMS2093K04
I06-0692
I06-0693
JZP-7
L000520
LS-83828
LS-83890
Lopac-R-4152
Lopac0_001101
 
MolPort-003-666-598
MolPort-003-987-439
NCGC00015893-01
NCGC00015893-04
NCGC00094373-01
NCGC00096064-01
NCGC00096064-02
NVD-434
R 4152
ReQuip
ReQuip CR
ReQuip LP
ReQuip XL
ReQuip XR
Repreve
Requip (TN)
Ropinirol
Ropinirol [INN-Spanish]
Ropinirole
Ropinirole (INN)
Ropinirole HCl
Ropinirole [INN:BAN]
Ropinirole hydrochloride
Ropinirole hydrochloride (JAN/USAN)
Ropinirole hydrochloride [USAN]
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor
Ropitor (TN)
SK&F 101468
SK&F 101468-A
SK&F-101,468
SK&F-101468-A
SK&F-101468A
SKF 101468
SKF 101468-A
SPECTRUM1505178
ST51051236
TL8005858
TL8005859
UNII-030PYR8953
UNII-D7ZD41RZI9
ropinirol
48
Bromocriptineapproved, investigationalPhase 33125614-03-331101
Synonyms:
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
(6aR,9R)-5-Bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-alpha-(2-methylpropyl)ergotamin-3',6',18-trione
2-Bromo-alpha-ergocryptine
2-Bromo-alpha-ergokryptin
2-Bromo-alpha-ergokryptine
2-Bromoergocryptine Methanesulfonate
2-Bromoergokryptine
2-bromo-α-ergocryptine
2-bromo-α-ergokryptin
2-bromo-α-ergokryptine
22260-51-1 (mesylate (salt))
25614-03-3
AC-13601
AC1L1KXS
AC1Q2716
Alti-Bromocriptine
Apo-Bromocriptine
BIDD:GT0464
BPBio1_001131
BRD-K14496212-001-01-1
Bagren
Biomol-NT_000005
Bromergocryptine
Bromocriptin
Bromocriptina
Bromocriptina [INN-Spanish]
Bromocriptine (USAN/INN)
Bromocriptine Methanesulfonate
Bromocriptine [BAN]
Bromocriptine [USAN:BAN:INN]
 
Bromocriptine methanesulfonate
Bromocriptinum
Bromocriptinum [INN-Latin]
Bromocryptin
Bromocryptine
Bromoergocriptine
Bromoergocryptine
C06856
C32H40BrN5O5
CB-154
CCRIS 3244
CHEBI:3181
CHEMBL493
CID31101
D03165
DB01200
EINECS 247-128-5
Ergocryptine, 2-bromo- (8CI)
Ergoset
LS-64540
Lopac0_000171
MolPort-002-512-064
NCGC00024584-04
NCI60_001365
NSC169774
PDSP2_001500
Parlodel
Parlodel Snaptabs
Prestwick0_000121
Prestwick1_000121
Prestwick2_000121
SPBio_002101
UNII-3A64E3G5ZO
bromocriptine
nchembio873-comp18
49
DeferiproneapprovedPhase 2, Phase 35730652-11-02972
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
APO-066
CP-20
DN-180-01-AF
Deferipron
 
Deferiprona
Deferiproni
Deferipronum
Deferypron
Dimethylhydroxypyridone
Défériprone
Ferriprox
PL-1
50
CeftriaxoneapprovedPhase 311973384-59-55479530, 5361919
Synonyms:
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
104376-79-6
104376-79-6 (di-hydrochloride salt)
73384-59-5
74578-69-1 (di-hydrochloride salt, hemiheptahydrate)
7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
AC-1592
AC1NUIFE
Biotrakson
C06683
C18H18N8O7S3
CEFTRIAXONE SODIUM
CHEBI:29007
CHEMBL161
CID5479530
CTRX
Cefatriaxone
Ceftriaxon
Ceftriaxona
Ceftriaxona [INN-Spanish]
 
Ceftriaxone (INN)
Ceftriaxone (TN)
Ceftriaxone [USAN:JAN]
Ceftriaxone intravenous
Ceftriaxone, Disodium Salt
Ceftriaxone, Disodium Salt, Hemiheptahydrate
Ceftriaxonum
Ceftriaxonum [INN-Latin]
Ceftriazone
D07659
DB01212
DRG-0071
EINECS 277-405-6
LS-150031
Longacef
Longaceph
MolPort-005-933-495
Ro 139904
Ro-13-9904
Ro13-9904
Rocefin
Rocephin
Rocephine
UNII-75J73V1629
ceftriaxone

Interventional clinical trials:

(show top 50)    (show all 620)
idNameStatusNCT IDPhase
1Non-Invasive Ventilation in Amyotrophic Lateral SclerosisUnknown statusNCT00560287Phase 4
2Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal SpasticityUnknown statusNCT01786005Phase 4
3Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)CompletedNCT00613899Phase 4
4CARE Canadian ALS Riluzole EvaluationCompletedNCT00542412Phase 4
5Mexiletine for the Treatment of Muscle Cramps in ALSCompletedNCT01811355Phase 4
6Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular AtrophyCompletedNCT00851461Phase 4
7Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive SymptomsCompletedNCT00297778Phase 4
8Diaphragmatic Reinnervation of Tetraplegic Patients With Respiratory InsufficiencyCompletedNCT01350297Phase 4
9Effects of Functional Electrical Stimulation on Gait in Children With Cerebral PalsyNot yet recruitingNCT02462018Phase 4
10Enhancing STDP After Spinal Cord InjuryNot yet recruitingNCT02701777Phase 4
11Modeling and Treating the Pathophysiology of Demyelination in Multiple SclerosisTerminatedNCT00854750Phase 4
12Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral SclerosisUnknown statusNCT00706147Phase 2, Phase 3
13Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)Unknown statusNCT00876772Phase 2, Phase 3
14Study of Creatine Monohydrate in Patients With Amyotrophic Lateral SclerosisUnknown statusNCT00069186Phase 3
15Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower LimbUnknown statusNCT01829763Phase 3
16Multicenter Rehabilitation Study in Acute StrokeUnknown statusNCT00849303Phase 2, Phase 3
17Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron DiseaseCompletedNCT01776970Phase 2, Phase 3
18LIME Study (LFB IVIg MMN Efficacy Study)CompletedNCT01951924Phase 3
19Phase 3 Study of Dexpramipexole in ALSCompletedNCT01281189Phase 3
20Noninvasive Ventilation in ALS Patients With Mild Respiratory InvolvementCompletedNCT00386464Phase 2, Phase 3
21Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)CompletedNCT00353665Phase 2, Phase 3
22Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00125203Phase 2, Phase 3
23Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral SclerosisCompletedNCT00833820Phase 2, Phase 3
24A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00444613Phase 2, Phase 3
25Clinical Trial Ceftriaxone in Subjects With ALSCompletedNCT00349622Phase 3
26Safety and Efficacy of AVP-923 in PBA Patients With ALS or MSCompletedNCT00573443Phase 3
27Minocycline to Treat Amyotrophic Lateral SclerosisCompletedNCT00047723Phase 3
28Trial of Sodium Valproate in Amyotrophic Lateral SclerosisCompletedNCT00136110Phase 3
29Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01933321Phase 2, Phase 3
30Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) TrialCompletedNCT00035815Phase 3
31Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00330681Phase 3
32Safety Extension Study of TRO19622 in ALSCompletedNCT01285583Phase 2, Phase 3
33Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00868166Phase 2, Phase 3
34The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02588677Phase 2, Phase 3
35The Effect of GCSF in the Treatment of ALS PatientsCompletedNCT01825551Phase 2, Phase 3
36Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral SclerosisCompletedNCT01492686Phase 3
37Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and ControlsCompletedNCT01160263Phase 3
38Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00424463Phase 3
39Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification IIICompletedNCT00415519Phase 3
40Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALSCompletedNCT00372879Phase 3
41Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALSCompletedNCT00021697Phase 3
42A Trial of Hydroxyurea in Spinal Muscular AtrophyCompletedNCT00485511Phase 2, Phase 3
43Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)CompletedNCT00774423Phase 2, Phase 3
44Escitalopram (Lexapro) for Depression MS or ALSCompletedNCT00965497Phase 3
45A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)CompletedNCT02292537Phase 3
46A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular AtrophyCompletedNCT02193074Phase 3
47Short and Long Term Treatment With 4-AP in Ambulatory SMA PatientsCompletedNCT01645787Phase 2, Phase 3
48Evaluation of the Safety and Performance of the NESS L300 Plus SystemCompletedNCT01237860Phase 3
49Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaCompletedNCT00627640Phase 3
50MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistCompletedNCT00605683Phase 3

Search NIH Clinical Center for Motor Neuron Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Motor Neuron Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Motor Neuron Disease:
Embryonic stem cell-derived motor neuron transplantation to treat paralysis
Embryonic/Adult Cultured Cells Related to Motor Neuron Disease:
Neuronal progenitor cells

Genetic Tests for Motor Neuron Disease

About this section

Anatomical Context for Motor Neuron Disease

About this section

MalaCards organs/tissues related to Motor Neuron Disease:

36
Spinal cord, Brain, Eye, Testes, Breast, Skeletal muscle, Cortex

FMA organs/tissues related to Motor Neuron Disease:

17
The motor neurones

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Motor Neuron Disease:
id TissueAnatomical CompartmentCell Relevance
1 Neural TubeMotor Neural Progenitor DomainMotor Neural Progenitor Cells Potential therapeutic candidate
2 Neural TubeMotor Neural Progenitor DomainMotor Neurons Affected by disease

Publications for Motor Neuron Disease

About this section

Articles related to Motor Neuron Disease:

(show top 50)    (show all 756)
idTitleAuthorsYear
1
Motor neuron disease: Brain-computer interface unlocks the mind of a patient with ALS. (27909307)
2017
2
Risk factors for respiratory failure of motor neuron disease in a multiracial Asian population. (28089419)
2017
3
Hereditary spastic paraplegia: More than an upper motor neuron disease. (28449883)
2017
4
Voltage-Gated Potassium Channel Antibodies in Slow-Progression Motor Neuron Disease. (27710962)
2017
5
Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. (28072907)
2017
6
Motor neuron disease mortality and lifetime petrol lead exposure: Evidence from national age-specific and state-level age-standardized death rates in Australia. (27992849)
2017
7
The death wish and motor neuron disease! The chameleons and new research optimism. (28084230)
2017
8
Motor Neuron Disease Presenting With Acute Respiratory Failure: A Case Study. (28503469)
2017
9
Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease. (28067943)
2017
10
Motor neuron disease: C9orf72 repeat expansion linked to aggressive disease in male patients with spinal-onset ALS. (27739539)
2016
11
Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. (27834214)
2016
12
Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. (28089114)
2016
13
Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation. (27892702)
2016
14
An autopsy-verified case of FTLD-TDP type A with upper motor neuron-predominant motor neuron disease mimicking MM2-thalamic-type sporadic Creutzfeldt-Jakob disease. (27929803)
2016
15
Traumatic Brain Injury Results in Cellular, Structural and Functional Changes Resembling Motor Neuron Disease. (27566977)
2016
16
Geographic distributions of motor neuron disease mortality and well water use in U.S. counties. (28019106)
2016
17
Closing in on an infectious etiology of motor neuron disease. (27664984)
2016
18
Development of patient decision support tools for motor neuron disease using stakeholder consultation: a study protocol. (27053272)
2016
19
Motor neuron disease triggering takotsubo syndrome. (27525372)
2016
20
CHCHD10 mutations and motor neuron disease: the distribution in Finnish patients. (27810918)
2016
21
Neuromuscular Ultrasound in the Assessment of Polyneuropathies and Motor Neuron Disease. (27035248)
2016
22
Neurofilaments in CSF As Diagnostic Biomarkers in Motor Neuron Disease: A Meta-Analysis. (27965574)
2016
23
HIV-associated motor neuron disease: HERV-K activation and response to antiretroviral therapy. (27664983)
2016
24
Enacting Varieties of Subjectivity Through Practices of Care: A Story of Living With Motor Neuron Disease. (25918113)
2016
25
The frontotemporal dementia-motor neuron disease continuum. (26987909)
2016
26
Pigment retinopathy in warmblood horses with equine degenerative myeloencephalopathy and equine motor neuron disease. (27491953)
2016
27
The End-of-Life Experiences of People with Motor Neuron Disease: Family Carers' Perspectives. (27135175)
2016
28
Analysis of terms used for the diagnosis and classification of amyotrophic lateral sclerosis and motor neuron disease. (27188215)
2016
29
Motor neuron disease: Nusinersen potentially effective in SMA. (28009016)
2016
30
Quo vadis motor neuron disease? (27019797)
2016
31
Eosinophilic Enteritis in Horses with Motor Neuron Disease. (27015868)
2016
32
Trends in motor neuron disease: association with latitude and air lead levels in Spain. (27098242)
2016
33
Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association. (26913547)
2016
34
Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. (26538301)
2016
35
WES in a family trio suggests involvement of TECPR2 in a complex form of progressive motor neuron disease. (27406698)
2016
36
Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. (26847526)
2016
37
Primary Lateral Sclerosis and Early Upper Motor Neuron Disease: Characteristics of a Cross-Sectional Population. (26905909)
2016
38
Motor neuron disease mortality rates in U.S. states are associated with well water use. (27324739)
2016
39
Abnormal response of distal Schwann cells to denervation in a mouse model of motor neuron disease. (26853136)
2016
40
Concurrent Equine Degenerative Myeloencephalopathy and Equine Motor Neuron Disease in Three Young Horses. (27298214)
2016
41
Motor neuron disease: Loss of MHCI exposes motor neurons to astrocyte-mediated toxicity. (26988907)
2016
42
Executive dysfunction and survival in patients with amyotrophic lateral sclerosis: Preliminary report from a Serbian centre for motor neuron disease. (27494074)
2016
43
Experiences and reflections of patients with motor neuron disease on breaking the news in a two-tiered appointment: a qualitative study. (26839121)
2016
44
Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation. (27070121)
2016
45
Motor neuron disease: Environmental toxins - modifiable risk factors for ALS? (27231185)
2016
46
Scintigraphic Evaluation of Mild to Moderate Dysphagia in Motor Neuron Disease. (26914558)
2016
47
A monster that lives in our lives": experiences of caregivers of people with motor neuron disease and identifying avenues for support. (27125270)
2016
48
Progress in respiratory management of bulbar complications of motor neuron disease/amyotrophic lateral sclerosis? (27520438)
2016
49
Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. (27822919)
2016
50
Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. (28040732)
2016

Variations for Motor Neuron Disease

About this section

Expression for genes affiliated with Motor Neuron Disease

About this section
Search GEO for disease gene expression data for Motor Neuron Disease.

Pathways for genes affiliated with Motor Neuron Disease

About this section

Pathways related to Motor Neuron Disease according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.9DCTN1, INA, NEFH
29.7DCTN1, MAPT, RAB5A, VCP
3
Show member pathways
9.5ALS2, NEFH, RAB5A, SLC1A2, SOD1
49.5DCTN1, MAPT, NEFH, SLC1A2, SOD1, TARDBP

GO Terms for genes affiliated with Motor Neuron Disease

About this section

Cellular components related to Motor Neuron Disease according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1Gemini of coiled bodiesGO:009750410.9SMN1, SMN2
2axolemmaGO:003067310.9MAPT, SLC1A2
3neurofibrillary tangleGO:009741810.8MAPT, NEFH
4neurofilamentGO:000588310.8INA, NEFH
5perikaryonGO:004320410.6NAIP, SMN1, SMN2
6SMN complexGO:003279710.6SMN1, SMN2
7cytoplasmic ribonucleoprotein granuleGO:003646410.5INA, MAPT, SMN1, SMN2
8neuron projectionGO:004300510.4ALS2, NAIP, SMN1, SMN2, SOD1
9SMN-Sm protein complexGO:003471910.4SMN1, SMN2
10neuronal cell bodyGO:004302510.2ALS2, MAPT, NAIP, RAB5A, SOD1
11myelin sheathGO:004320910.2INA, NEFH, SOD1, SOD2, VCP
12axonGO:003042410.1ALS2, CNTF, MAPT, NEFH, RAB5A, SLC1A2
13protein complexGO:004323410.1ALS2, AR, DCTN1, SOD1, VCP
14somatodendritic compartmentGO:003647710.0MAPT, RAB5A
15cytoplasmGO:00057378.5ALS2, AR, CNTF, DCTN1, MAPT, NAIP

Biological processes related to Motor Neuron Disease according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1DNA-templated transcription, terminationGO:000635310.9SMN1, SMN2
2astrocyte activationGO:004814310.8CNTF, MAPT
3hydrogen peroxide biosynthetic processGO:005066510.8SOD1, SOD2
4intermediate filament cytoskeleton organizationGO:004510410.8INA, NEFH
5nuclear importGO:005117010.7SMN1, SMN2
6positive regulation of superoxide anion generationGO:003293010.7MAPT, SOD1
7positive regulation of microtubule polymerizationGO:003111610.6DCTN1, MAPT
8locomotory behaviorGO:000762610.6ALS2, SOD1, SOD2
9removal of superoxide radicalsGO:001943010.5SOD1, SOD2
10regulation of endosome sizeGO:005103610.5ALS2, RAB5A
11neurofilament cytoskeleton organizationGO:006005210.5INA, NEFH, SOD1
12response to superoxideGO:000030310.4SOD1, SOD2
13negative regulation of neuron apoptotic processGO:004352410.4CNTF, NAIP, SOD1, SOD2
14response to axon injuryGO:004867810.2NAIP, SOD1, SOD2
15superoxide anion generationGO:004255410.1SOD1, SOD2
16nervous system developmentGO:00073999.7CNTF, DCTN1, INA, NAIP, SLC1A2, SMN1

Molecular functions related to Motor Neuron Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1enzyme bindingGO:001989910.2AR, MAPT, SOD1, SOD2, SQSTM1
2superoxide dismutase activityGO:000478410.1SOD1, SOD2
3identical protein bindingGO:00428029.2MAPT, SMN1, SMN2, SOD1, SOD2, SQSTM1

Sources for Motor Neuron Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet